News Releases

Taiho Pharmaceutical Co., Ltd. announced today that the marketing of its β-lactamase inhibitor combination antibiotic ZOSYN_® 2.25 and ZOSYN_® 4.5 for intravenous injection, and ZOSYN_® 4.5 for I.V. infusion bag (generic name: tazobactam and piperacillin) will be transferred to Taiho Pharmaceutical from the existing marketer, Taisho Toyama Pharmaceutical Co., Ltd., as of April 1, 2019.

ZOSYN is an injectable antibacterial combination product consisting of the β-lactamase inhibitor tazobactam, which Taiho Pharmaceutical discovered, and the semisynthetic antibiotic piperacillin, which Toyama Chemical Co., Ltd. (Now: Fujifilm Toyama Chemical Co., Ltd. ) discovered, in a ratio of 1:8 in potency for intravenous administration.

In July 2008, Taiho Pharmaceutical received marketing authorization for ZOSYN, co-developed with Toyama Chemical, in Japan for indications of septicemia, pneumonia, pyelonephritis, and complicated cystitis in adults and children. Approval was then received for the indications of peritonitis, intra-abdominal abscess, cholecystitis, and cholangitis in September 2012, for febrile neutropenia in June 2015, and for additional indications of complicated skin and soft tissue infections in May 2017. It is recommended as a first choice in the guidelines issued by medical societies including those in and outside Japan for the treatment of various infectious diseases, and ZOSYN is well recognized as a standard therapeutic agent for bacterial infections around the world.

Taiho Pharmaceutical remains committed to making further contributions to patients and to medical practitioners engaged in the treatment of infectious diseases.